Professor of Surgery, University Mich Medical School
General Surgery
Dr. Diane M. Simeone, MD
|
|
Give Review
Diane Simeone works in the field of General Surgery. He studied medicine at Duke University School of Medicine. Duke University School of Medicine is a top medical university. Duke University School of Medicine is ranked 8 in research and 29 in primary care medicine He has 5 awards "America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Elected Member" and "Fellow (FACS)". Diane M. Simeone is a published MD as well. He has 99 publications published. The latest was: ATDC (Ataxia Telangiectasia Group D Complementing) Promotes Radioresistance through an Interaction with the RNF8 Ubiquitin Ligase. Diane Simeone is registered with Medicare.
Publications
- ATDC (Ataxia Telangiectasia Group D Complementing) Promotes Radioresistance through an Interaction with the RNF8 Ubiquitin Ligase.
- Large-Scale Identification of Core-Fucosylated Glycopeptide Sites in Pancreatic Cancer Serum Using Mass Spectrometry.
- Proteins associated with pancreatic cancer survival in patients with resectable pancreatic Ductal adenocarcinoma.
- CD44 regulates pancreatic Cancer invasion through MT1-MMP.
- A radial flow microfluidic device for ultra-high-throughput affinity-based isolation of circulating tumor cells.
- Expansion of CTCs from early stage lung Cancer patients using a microfluidic co-culture model.
- Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic Neuroendocrine tumors.
- Quantitative Analysis of Single Amino Acid Variant Peptides Associated with Pancreatic Cancer in Serum by an Isobaric Labeling Quantitative Method.
- A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic Cancer.
- Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic AdenoCarcinoma.
- Tumor-Associated Macrophages Produce Interleukin 6 and Signal via STAT3 to Promote Expansion of Human Hepatocellular Carcinoma Stem Cells.
- Recent advances in Pancreatic surgery.
- Microfluidic device (ExoChip) for on-chip isolation, quantification and characterization of circulating exosomes.
- Postbrushing and fine-needle aspiration biopsy follow-up and treatment options for patients with pancreatoBiliary lesions: The papanicolaou society of cytopathology gu...
- Glycoprotein Biomarker Panel for Pancreatic Cancer Discovered by Quantitative Proteomics Analysis.
- Novel Neutralizing Hedgehog Antibody MEDI-5304 Exhibits Antitumor Activity by Inhibiting Paracrine Hedgehog Signaling.
- Clinical evaluation, imaging studies, indications for cytologic study, and preprocedural requirements for Duct brushing studies and pancreatic FNA: The papanicolaou so...
- ATDC/TRIM29 phosphorylation by ATM/ MAPKAP kinase 2 mediates radioresistance in pancreatic Cancer cells.
- Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of Abdominal radiology and the american pancreatic association.
- Antibody against CD44s Inhibits Pancreatic Tumor Initiation and Post-Radiation Recurrence in Mice.
- In vivo optical spectroscopy for improved detection of pancreatic adenoCarcinoma: a feasibility study.
- HAb18G/CD147 Promotes pSTAT3-Mediated Pancreatic Cancer Development via CD44s.
- Specific Glycoforms of MUC5AC and Endorepellin Accurately Distinguish Mucinous from Nonmucinous Pancreatic Cysts.
- Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets.
- Deciphering the role of stroma in pancreatic Cancer.
- A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic Cancer.
- Canonical Wnt Signaling Is Required for Pancreatic Carcinogenesis.
- Breast Cancer Metastases to the Pancreas.
- Biology and clinical applications of pancreatic Cancer stem cells.
- The role of cytology in the preoperative assessment and management of patients with pancreaticoBiliary tract neoplasms.
- Bmi1 enhances tumorigenicity and Cancer stem cell function in pancreatic adenocarcinoma.
- Outlier Kinase Expression by RNA Sequencing as Targets for Precision Therapy.
- PKA Modulates TGF-beta Signaling through a Direct Interaction with Smad4.
- Plasma Shh levels reduced in pancreatic Cancer patients.
- Emerging frontiers in pancreatic Cancer research: elaboration of key genes, cells and the extracellular milieu.
- Sensitization of pancreatic Cancer stem cells to gemcitabine by chk1 inhibition.
- An N-glycosylation Analysis of Human Alpha-2-Macroglobulin Using an Integrated Approach.
- A Phase I/II Trial of Intensity Modulated Radiation (IMRT) Dose Escalation With Concurrent Fixed-dose Rate Gemcitabine (FDR-G) in Patients With Unresectable Pancreatic...
- Identification of Glycoprotein Markers for Pancreatic Cancer CD24(+)CD44(+) Stem-like Cells Using Nano-LC-MS/MS and Tissue Microarray.
- Comparison of Surgical and Endoscopic Sample Collection for Pancreatic Cyst Fluid Biomarker Identification.
- Pancreatic Cancer stem cell biology and its therapeutic implications.
- 2011 american Pancreatic association presidential address: demystifying the pancreas.
- Minutes of the business meeting of the american Pancreatic association friday, november 5, 2010, chicago, illinois.
- Contemporary Management of Nonfunctioning Pancreatic Neuroendocrine Tumors.
- Advances in pancreatic Cancer.
- c-Met is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target.
- A multiplexed bead assay for profiling glycosylation patterns on serum protein biomarkers of pancreatic Cancer.
- Mass spectrometric assay for analysis of haptoglobin fucosylation in pancreatic Cancer.
- Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.
- Is there still a glass ceiling for women in academic surgery?
- Enhanced discrimination of malignant from benign pancreatic Disease by measuring the CA 19-9 antigen on specific protein carriers.
- Glycoprotein analysis using protein microarrays and mass spectrometry.
- Reliable gene expression measurements from fine needle aspirates of pancreatic Tumors: effect of amplicon length and quality assessment.
- Quantitative proteomic profiling studies of pancreatic Cancer stem cells.
- Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
- Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of Pancreatic cystic neoplasms.
- New frontiers in pancreatic Cancer research.
- In vivo bioluminescent imaging of irradiated orthotopic pancreatic Cancer xenografts in nonobese diabetic-severe combined immunodeficient mice: a novel method for targ...
- The evolution of the SUS.
- Cancer stem cells: a new theory regarding a timeless disease.
- Pancreatic Cancer stem cells and relevance to Cancer treatments.
- Oncogenic function of ATDC in pancreatic Cancer through Wnt pathway activation and beta-catenin stabilization.
- Pancreatic Cancer serum detection using a lectin/glyco-antibody array method.
- All-liquid separations, protein microarrays, and mass spectrometry to interrogate serum proteomes: an application to serum glycoproteomics.
- Identification of human pancreatic Cancer stem cells.
- Pancreatic Cancer stem cells: implications for the treatment of pancreatic Cancer.
- SSAT/AGA/ASGE state of the art conference on cystic neoplasms of the pancreas.
- Regulation of transforming growth factor beta-induced responses by protein kinase A in Pancreatic acinar cells.
- Pancreatic Cancer stem cells.
- Enhanced detection of autoantibodies on protein microarrays using a modified protein digestion technique.
- "Criminal" profiling of the pancreas: when is aggressive therapy indicated for a non-aggressive entity?
- Human pancreatic Cancer stem cells: implications for how we treat pancreatic Cancer.
- Early detection and biomarkers in pancreatic Cancer.
- Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic Cancer.
- Phenotypic characterization of human colorectal Cancer stem cells.
- Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic Cancer sera.
- CEACAM1, a novel serum biomarker for pancreatic Cancer.
- Cancer stem cells: a new paradigm for understanding tumor progression and therapeutic resistance.
- Adrenomedullin is expressed in pancreatic Cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor, ADMR.
- N-linked glycosylation profiling of pancreatic Cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis.
- Identification of pancreatic Cancer stem cells.
- Total pancreatectomy: indications, operative technique, and postoperative sequelae.
- Islet hypertrophy following Pancreatic disruption of Smad4 signaling.
- Screening of glycosylation patterns in serum using natural glycoprotein microarrays and multi-lectin fluorescence detection.
- Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic Cancer serum.
- Adjuvant treatment strategies for pancreatic Cancer.
- Identification of a putative tumor suppressor gene Rap1GAP in pancreatic Cancer.
- Identification of a Specific Vimentin Isoform That Induces an Antibody Response in Pancreatic Cancer.
- S100P promotes pancreatic Cancer growth, survival, and invasion.
- The molecular basis of pancreatic fibrosis: common stromal gene expression in chronic pancreatitis and pancreatic adenoCarcinoma.
- Raf kinase inhibitory protein inhibits beta-cell proliferation.
- An autoantibody-mediated immune response to calreticulin isoforms in pancreatic Cancer.
- Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic Cancer.
- A transforming growth factor beta-induced Smad3/Smad4 complex directly activates protein kinase A.
- S100P stimulates cell proliferation and survival via receptor for activated glycation end proDucts (RAGE).
- Increased MMP-9 expression and activity by aortic smooth muscle cells after nitric oxide synthase inhibition is associated with increased nuclear factor-kappaB and act...
- Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic Cancer.
- Bacillus anthracis as an agent of bioterrorism: a review emphasizing surgical treatment.
Schools
Duke University School Of Medicine
University Of Michigan
Procedures Preformed
- Adrenalectomy
- Appendectomy, Open
- Dressing and-or Debridement of Wound, Infection, or Burn (incl. Negative Pressure Wound Therapy)
- Enterostomy (Laparoscopic or Open)
- View All
Conditions Treated
- Abdominal Pain
- Atelectasis
- Bile Duct Cancer
- Biliary Atresia
- View All
Doctors Specialties
- General Surgery
Accepted Insurances
- Choice Plus POS II
- Amerigroup (Wellpoint)
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Blue Care Network PCP Focus Network
- Group Employees PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Cofinity PPO
- Commercial Insurance Company
- First Health (Coventry Health Care) PPO
- Frontpath Health Coalition
- Health Alliance
- Choice Care PPO
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- Priority PPO
- Tricare
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Elected Member
- Fellow (FACS)
Education
-
University of Michigan Hospitals and Health Centers -
Duke University School of Medicine
Hospital
-
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1215038138 | |
| NPPES Provider LastName | SIMEONE | |
| NPPES Provider FirstName | DIANE | |
| NPPES Provider ZIPCode | 481095332 | |
| NPPES Provider State | MI | |
| Specialty Description | General Surgery | |
| Total Claim Count | 61.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1215038138 |
| Last Name Of The Provider | SIMEONE |
| First Name Of The Provider | DIANE |
| View All |
Similar Doctors
|
|
Dr. Peter Sassalos, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Suzanne E. Jones, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Englesbe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dawn M. Coleman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenneth J. Woodside, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael S. Sabel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arnold G. Coran, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick E. Georgoff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John C. Magee, MD |
|
|
Dr. Alex C. Kim, MD |
|
|
Dr. Yekaterina Polyatskaya, MD |
|
|
Dr. Mark A. Healy, MD |
|
|
Dr. Nicole L. Werner, MD
This Doctor is OpenDoctor Recommended.
|